Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.

Peripheral Neuropathy Due to Chemotherapy Clinical Trial

Official title:

Fall Risk and Quality of Life: Influence of Dual Task Performance, Cognition, and Sensorimotor Variables in Individuals With Cancer Treatment Related Peripheral Neuropathy.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06313359
• Other study ID #: FY2024-125
• Status: Not yet recruiting
• Start date: March 20, 2024
• Est. completion date: June 2025

Study information

• Verified date: March 2024
• Source: Texas Woman's University
• Contact: Priya Karakkattil
• Phone: 12148625624
• Email: Pkarakkattil[@]twu.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer. Specifically, we are interested to find out if you have any difficulty with thinking, feeling, balancing, or moving around that will contribute to risk for falls or quality of life. We are also interested to see if you have any difficulty with doing two activities at the same time, such as walking and texting.

Description:

Cancer related cognitive impairment (CRCI) is a common side effect of treatment of cancer during and after chemotherapy and is seen in patients with non-central nervous system( non-CNS) cancer (Lange, Joly, et al., 2019; Pendergrass et al., 2018). Though common after chemotherapy, other treatments such as hormone therapies and targeted therapies can also cause cognitive deficits.(Lange, Joly, et al., 2019). The self-reported prevalence of cognitive complains in cancer survivors was 75% in a large web based study with non CNS cancers (Lange, Licaj, et al., 2019). The clinical presentation of these cognitive impairments include memory deficits, difficulty with learning attention, concentration, reasoning, processing speed, executive functions and visuospatial skills(Mounier et al., 2020). Therefore the cognitive impairment can have a negative impact on quality of life, daily functioning and ability to work in patients with cancer while undergoing treatment and while in remission(Pendergrass et al., 2018). Acquired Peripheral Neuropathy (APN) is another common side effect of treatment for cancer. While majority of the peripheral neuropathy symptoms are due to neurotoxic chemotherapy agents resulting in chemotherapy-induced peripheral neuropathy (CIPN), neuropathy symptoms can also occur as paraneoplastic, immune-mediated, or neoplastic neuropathies.(Staff et al., 2017). The reported prevalence of CIPN is 68% within first month after chemotherapy and continued to be present in 47% of the survivors even 6 years later(Autissier, 2019). The clinical presentation of the CIPN includes numbness, tingling, or burning, neuropathic pain, decrease of muscle tone and coordination, and loss of balance(Autissier, 2019). The symptoms tends to begin distally in the fingers and toes and moves proximally through the extremities (Autissier, 2019). CIPN is typically associated with treatment using platinum based drugs, taxanes, epothilones, vinca alkaloids, bortezomib and thalidomide (Hu et al., 2019). Individuals with CIPN are significantly more likely to suffer falls and fall related injuries (Autissier, 2019). In breast cancer survivors with neuropathy, 40.9% experienced falls on both flat surfaces and non-flat surfaces during upright activities(Komatsu et al., 2019). Gait is a complex functional activity that requires the integration of the musculoskeletal, sensory, neurological, and cognitive systems(Fritz & Lusardi, 2009). Significant gait variability in step width and step length with forward walking has been reported in cancer survivors with peripheral neuropathy compared to healthy controls(Hsieh et al., 2019). However, normal daily walking does not include just walking in a forward direction, but rather it involves walking in different directions such as walking backwards to sit in a chair. Although gait variability has been reported with forward walking, the gait variability while walking backwards in patients with cancer with APN has not been investigated previously. Cognitive impairment has been strongly associated with decreased performance in dual task abilities and higher number of falls in older adults (Allali et al., 2017; Li & Harmer, 2020). Performing concurrent tasks such as walking and talking or walking and texting is a normal aspect of life. Concurrent performance of two tasks with distinct motor and cognitive demands has been associated with increased fall risk in older adults(Belur et al., 2020). Ability to do such dual task (DT) has shown to be declined in persons with cognitive and motor impairments(Abou et al., 2022; Bryk et al., 2023; Ozkul et al., 2021). Ability to perform DT has been also reported to be affected in persons with diabetic peripheral neuropathy (Parveen & Noohu, 2023). There is only one reported study that evaluated the cognitive and sensory deficits associated with orbital stability in gait on treadmill during single and dual task in cancer survivors with and without peripheral neuropathy(Monfort et al., 2019). However, walking on the treadmill at fixed speed does not translate to the real-world adaptations on overground walking in different directions with the added challenge of a cognitive task. Though cognitive and peripheral neuropathy symptoms are reported in patients with non- CNS cancers who are undergoing treatment and while in remission, ability to perform dual task with forward and backward walking has not been assessed in this population and not compared with an age and gender matched control without peripheral neuropathy. Additionally, it is important to investigate what cognitive, motor and sensory impairments can predict fall risk and decreased quality of life in this population compared to an age and gender matched control. The purpose of this proposed exploratory pilot study is to evaluate the dual task cost of variable walking in individuals diagnosed with cancer treatment induced peripheral neuropathy compared to age and gender matched individuals without peripheral neuropathy. backward walking on an over ground computerized mat. A secondary purpose will be to identify what type of cognitive, motor and sensory impairments can correlate quality of life in individuals diagnosed with cancer treatment induced peripheral neuropathy and can predict fall risk in this population compared to compared to age and gender.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: June 2025
• Est. primary completion date: March 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Experimental group

• Individuals 18 years and older
• diagnosed with non- CNS cancer who underwent treatment and presents with peripheral neuropathy symptoms. Control group
• age (+/- one year) and gender matched individuals
• no diagnosed peripheral neuropathy
• No diagnosed cognitive symptoms.

Exclusion Criteria:

• Unable to follow two step commands.
• Unable to ambulate x 50 feet independently without use of an assistive device.
• Unable to use a phone to send text messages.
• Diagnosis of diabetic peripheral neuropathy
• Diagnosis of CNS cancer.
• Unable to speak/understand English

Related Conditions & MeSH terms

• Peripheral Nervous System Diseases
• Peripheral Neuropathy Due to Chemotherapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Texas Woman's University

References & Publications (7)

Autissier E. Chemotherapy-Induced Peripheral Neuropathy: Association With Increased Risk of Falls and Injuries. Clin J Oncol Nurs. 2019 Aug 1;23(4):405-410. doi: 10.1188/19.CJON.405-410. — View Citation

Komatsu H, Yagasaki K, Komatsu Y, Yamauchi H, Yamauchi T, Shimokawa T, Doorenbos AZ. Falls and Functional Impairments in Breast Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy. Asia Pac J Oncol Nurs. 2019 Jul-Sep;6(3):253-260. doi: 10.4103 — View Citation

Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter MB, Castel H. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019 Dec 1;30(12):1925-1940. doi: 10.1093/annonc/mdz410. — View Citation

Montero-Odasso M, Sarquis-Adamson Y, Kamkar N, Pieruccini-Faria F, Bray N, Cullen S, Mahon J, Titus J, Camicioli R, Borrie MJ, Bherer L, Speechley M. Dual-task gait speed assessments with an electronic walkway and a stopwatch in older adults. A reliabilit — View Citation

Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS. Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis. Life Sci. 2020 Oct 1;258:118071. doi: 10.1016/j.lfs.2020.118071. Epub 2020 Jul 14. — View Citation

Small GH, Brough LG, Neptune RR. The influence of cognitive load on balance control during steady-state walking. J Biomech. 2021 Jun 9;122:110466. doi: 10.1016/j.jbiomech.2021.110466. Epub 2021 Apr 23. — View Citation

Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fall risk	Fall risk will be assessed using the Timed Up and Go (TUG)-Test.(Blackwood & Rybicki, 2021) For the TUG, the participant will be asked to stand up from a chair, walk 3 m and touch a line on the floor, walk back to the chair and sit down. Timing of the test will begin when the tester gives the command "go" and will be stopped when the participant made contact with the chair as they sat down.	5 minutes
Primary	Quality of life- in cancer patients	Participants in the cancer related peripheral neuropathy group will complete the Functional Assessment of Cancer Therapy- General (FACT-G ) to assess self-reported quality of life.	5 minutes
Secondary	Trail Making Test (TMT) Parts A & B	TMT test assesses attention, psychomotor, and higher-level cognitive function and has been recommended to be used to in cancer population	5 minutes
Secondary	Single Task- Working Memory	Single task assessment of working memory will be assessed by randomly picking one of the following tests (serial sevens (7s), spelling words backwards or recite months backwards) for 30 seconds in seated position.	3 minutes
Secondary	Single Task- Visual Attention Cognitive Task	Visual-attention cognitive tasks will be tested by randomly selecting one of the following texting activity for 30 seconds (texting animal names, cities, or colors on a smart phone) in a seated position. (Belur et al., 2020)	3 minutes
Secondary	Protective Sensation	Protective sensation in the upper and lower extremities will be measured using the Semmes-Weinstein monofilament.	5 minutes
Secondary	Grip Strength	Grip strength will be assessed using a Jamar handheld dynamometer.	5 minutes
Secondary	LE strength assessment- HHD	Muscle strength testing of the ankle dorsiflexors, knee flexors, knee extensors, hip flexors, hip extensors and hip abductors using a handheld dynamometer using a make test.	10 minutes
Secondary	Dynamic Balance	Dynamic balance and coordination will be assessed using the Four-Square Step Test (FSST).	5 minutes
Secondary	Single Task- Gait Speed	For the single task gait component, we will utilize the Zeno© Electronic Walkway for assessing walking in both forward and backward directions using self-selected speed. Participants will commence/continue walking two feet prior to and after contacting the electronic walkway to account for acceleration and deceleration.	8 minutes
Secondary	Dual Task- Working Memory & Gait Speed - Composite measure	Participants will complete three trials of walking forward and three trials of walking backward with simultaneous execution of a randomly selected working memory task (serial sevens (7s), spelling words backwards or recite months backwards)	5 minutes
Secondary	Dual Task- Visual Attention Cognitive Task & Gait Speed - Composite measure	Participants will complete three trials of walking forward and three trials of walking backward with simultaneous execution of a randomly selected visual-attention cognitive task (texting animal names, cities, or colors on a smart phone)	5 minutes